IDH1 and cholangiocarcinoma: Moreover, Ivosidenib, an inhibitor of mutated IDH1 has shown encouraging results in a phase I trial including patients with CCA33 and is evaluated in a phase III trial in advanced cholangiocarcinoma (ClinicalTrials.gov identifier: NCT02989857).